华大智造拟受让三箭齐发及华大序风100%股权

Core Viewpoint - The company BGI Genomics (华大智造) announced a cash acquisition of 100% equity in Shenzhen Sanjian Qifa Technology Co., Ltd. and Hangzhou BGI Xifeng Technology Co., Ltd., focusing on advanced technologies in spatial omics and nanopore sequencing [1][2] Group 1: Acquisition Details - The total transaction price for the acquisition is set at 36,570 million yuan, with Sanjian Qifa valued at 15,800 million yuan and BGI Xifeng at 20,770 million yuan [1] - Following the acquisition, the company plans to inject additional capital of 7,000 million yuan into Sanjian Qifa and 6,000 million yuan into BGI Xifeng [1] Group 2: Strategic Implications - The acquisition will provide the company with control over two cutting-edge technology platforms, enhancing its competitive edge and profitability in the long term [1] - Sanjian Qifa and BGI Xifeng are expected to achieve profitability by 2026 and 2028, respectively, marking a significant step in the company's strategic layout [2] - This move is aimed at improving the company's technological ecosystem and boosting its independent innovation capabilities in the gene sequencing field [2]